Cantor Fitzgerald analyst Charles Duncan last night initiated coverage of Karuna Therapeutics with a Neutral rating and $214 price target. Karuna is a development-stage neuro-innovator developing muscarinic treatments for psychiatric disorders related to psychosis, including schizophrenia and Alzheimer’s disease psychosis, the analyst tells investors in a research note. The analyst says that while KarXT represents a "meaningful paradigm shift" in treating psychosis, its upside value potential is being obscured by "complexifiers" such as competition and a "non-zero risk" of limited use in elderly populations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on KRTX:
- Karuna Therapeutics initiated with a Neutral at Cantor Fitzgerald
- Karuna Therapeutics price target lowered to $257 from $262 at Wells Fargo
- Karuna Therapeutics reports Q4 EPS ($2.22), consensus ($2.25)
- Karuna Therapeutics signing exclusive global license agreement for TRPC4/5
- Karuna Therapeutics appoints William Kane as Chief Commercial Officer